🔎 Trials Near Me

Domov › Akutna mieločna levkemija › South Carolina › Greenville

Klinične študije za Akutna mieločna levkemija v Greenville, SC

10 študij za Akutna mieločna levkemija išče udeležence na lokacijah v Greenville in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.

Uradno besedilo študije (angleško)

Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Vključevanje udeležencevFaza 2
  • Prisma Health Cancer Institute - Butternut, Greenville
  • Prisma Health Cancer Institute - Faris, Greenville
  • Prisma Health Cancer Institute - Eastside, Greenville
Starost 18 in več · Vsi spoli · Posodobljeno 5. okt. 2026 · NCT05564390

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
  • Prisma Health Cancer Institute - Faris, Greenville
  • Prisma Health Greenville Memorial Hospital, Greenville
Starost 40–75 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT05334069

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Vključevanje udeležencevFaza 2
  • Prisma Health Cancer Institute - Butternut, Greenville
  • Prisma Health Cancer Institute - Faris, Greenville
  • Prisma Health Cancer Institute - Eastside, Greenville
Starost 18–59 · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT05554393

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Vključevanje udeležencevFaza 2
  • Prisma Health Cancer Institute - Butternut, Greenville
  • Prisma Health Cancer Institute - Faris, Greenville
  • Prisma Health Cancer Institute - Eastside, Greenville
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Vključevanje udeležencevFaza 2
  • Prisma Health Cancer Institute - Butternut, Greenville
  • Prisma Health Cancer Institute - Faris, Greenville
  • Prisma Health Cancer Institute - Eastside, Greenville
Starost 18–59 · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT05554406

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Vključevanje udeležencevFaza 2
  • Prisma Health Cancer Institute - Butternut, Greenville
  • Prisma Health Cancer Institute - Faris, Greenville
  • Prisma Health Cancer Institute - Eastside, Greenville
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT06317649

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Vključevanje udeležencevFaza 3
  • BI-LO Charities Children's Cancer Center, Greenville
6 Months – 21 Years · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT04293562

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Vključevanje udeležencevFaza 1/2
  • Bon Secours St. Francis Cancer Center, Greenville
Starost 12 in več · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT04588922

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Vključevanje udeležencevFaza 1
  • Prisma Health, Greenville
Starost 18 in več · Vsi spoli · Posodobljeno 20. avg. 2026 · NCT06001788

Študije za Akutna mieločna levkemija v drugih mestih

Druge študije v Greenville

Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.